SAN DIEGO, Dec. 30, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced it will be hosting a meeting for analysts and investors in New York on Wednesday, January 7, 2015 at 10:00 a.m. ET/ 7:00 a.m. PT. During the meeting, Halozyme's senior management and a physician expert will discuss the following topics:
- The science of PEGPH20 (Tumor Microenvironment and Mechanism of Action)
- An update on Halozyme's pancreatic cancer program
- Plans to evaluate PEGPH20 in additional tumors types (Non-Small Cell Lung Cancer)
- Evaluation of PEGPH20 in combination with Immuno-Oncology agents
The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including oncology, diabetes and dermatology that have significant unmet medical need today. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Janssen and Baxter. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning future actions relating to the development of PEGPH20 such as the anticipated enrollment and dosing of PEGPH20 in pancreatic cancer and NSCLC and the possibility that PEGPH20 may be used to address cancer) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including the possibility that the revised protocol may not address the apparent increased rate of thromboembolic events observed with the use of PEGPH20 in the trial or satisfy future regulatory requirements, the possibility of additional safety events, unexpected expenditures and costs, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2014.
Investor Contact: Schond Greenway Halozyme Therapeutics 858-704-8352 email@example.com
Media Contact: Susan Neath Francis 212-301-7182 firstname.lastname@example.org
SOURCE Halozyme Therapeutics, Inc.